It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LYPHF’s FA Score shows that 0 FA rating(s) are green whileSCLX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SCLX’s TA Score shows that 5 TA indicator(s) are bullish.
LYPHF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while SCLX (@Pharmaceuticals: Major) price change was -30.33% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -4.26%. For the same industry, the average monthly price growth was -5.33%, and the average quarterly price growth was +2.99%.
SCLX is expected to report earnings on May 12, 2023.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
LYPHF | SCLX | LYPHF / SCLX | |
Capitalization | 1.76B | 166M | 1,058% |
EBITDA | 907M | -109.1M | -831% |
Gain YTD | -27.744 | -66.667 | 42% |
P/E Ratio | 19.23 | N/A | - |
Revenue | 5.2B | 46.7M | 11,135% |
Total Cash | 5.51B | 3.92M | 140,525% |
Total Debt | 9.49B | 128M | 7,415% |
SCLX | |
---|---|
RSI ODDS (%) | 1 day ago90% |
Stochastic ODDS (%) | 1 day ago47% |
Momentum ODDS (%) | 1 day ago42% |
MACD ODDS (%) | 1 day ago40% |
TrendWeek ODDS (%) | 1 day ago65% |
TrendMonth ODDS (%) | 1 day ago82% |
Advances ODDS (%) | 10 days ago0% |
Declines ODDS (%) | 1 day ago86% |
BollingerBands ODDS (%) | 1 day ago62% |
Aroon ODDS (%) | 1 day ago21% |
A.I.dvisor tells us that LYPHF and MRK have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LYPHF and MRK's prices will move in lockstep.
Ticker / NAME | Correlation To LYPHF | 1D Price Change % | ||
---|---|---|---|---|
LYPHF | 100% | N/A | ||
MRK - LYPHF | 20% Poorly correlated | -0.14% | ||
OGN - LYPHF | 13% Poorly correlated | -1.92% | ||
SNYNF - LYPHF | 2% Poorly correlated | -4.17% | ||
SCLX - LYPHF | 2% Poorly correlated | -8.11% | ||
CSWYF - LYPHF | 1% Poorly correlated | N/A | ||
More |
A.I.dvisor tells us that SCLX and CSWYF have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCLX and CSWYF's prices will move in lockstep.
Ticker / NAME | Correlation To SCLX | 1D Price Change % | ||
---|---|---|---|---|
SCLX | 100% | -8.11% | ||
CSWYF - SCLX | 24% Poorly correlated | N/A | ||
GRFS - SCLX | 10% Poorly correlated | +5.06% | ||
MIRA - SCLX | 7% Poorly correlated | -3.85% | ||
PFE - SCLX | 5% Poorly correlated | -2.62% | ||
OGN - SCLX | 5% Poorly correlated | -1.92% | ||
More |